bosentan anhydrous has been researched along with Abnormality, Heart in 53 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 21 (39.62) | 29.6817 |
| 2010's | 27 (50.94) | 24.3611 |
| 2020's | 5 (9.43) | 2.80 |
| Authors | Studies |
|---|---|
| Mendel, B; Prakoso, R; Setiawan, M; Siagian, SN | 1 |
| Gorbachevsky, SV; Shmalts, AA | 1 |
| Betancourt-Montoya, M; Corona-Villalobos, C | 1 |
| Idris, N; Jeremiasen, I; Moledina, S; Tran, PK; Tran-Lundmark, K | 1 |
| Chen, M; Du, HA; Kuang, HY; Li, Q; Yin, YH | 1 |
| Gao, C; Liu, J; Wu, Y; Zhang, R; Zhao, M | 1 |
| Kuang, HY; Lu, TW; Shou, WN; Tian, J; Wu, C; Wu, YH; Yi, QJ | 1 |
| Beghetti, M; Broberg, CS; Budts, W; D'Alto, M; Diller, GP; Dimopoulos, K; Gatzoulis, MA; Giannakoulas, G; Gu, H; Opotowsky, AR; Swan, L; Veldtman, G | 1 |
| Hebert, A; Idorn, L; Jensen, AS; Søndergaard, L; Sørensen, KE | 1 |
| Crepaz, R; De Santis, S; Montanaro, D; Romeo, C | 1 |
| Deiros, L; Del Cerro, MJ; Gutierrez-Larraya, F; Herrero, A; Roldan, T; Romero, JA | 1 |
| Guo, L; Liu, YJ; Xie, ZL | 1 |
| Gao, C; Li, B; Shang, L; Sheng, W; Yao, M; Ye, W | 1 |
| Albini, A; Bacchi Reggiani, ML; Bachetti, C; Dardi, F; Galiè, N; Gotti, E; Manes, A; Mazzanti, G; Monti, E; Palazzini, M; Rinaldi, A | 1 |
| Goldberg, DJ; Paridon, SM; Rychik, J; Snarr, BS | 1 |
| Etnel, J; Helbing, WA; Mank, A; Oldenburger, NJ; Takkenberg, JJ | 1 |
| Dong, NG; Liu, M; Lu, R; Shang, XK; Wang, B; Xiao, SN; Zhang, CD; Zhang, X | 1 |
| Blok, IM; Bouma, BJ; Mulder, BJM; van Dijk, APJ; van Riel, ACMJ | 1 |
| Dimopoulos, K; Gatzoulis, MA; Giannakoulas, G; Wort, SJ | 1 |
| Book, WM; Lee, EK; Lyle, TA; McConnell, ME; Mehta, PK; Simpson, L | 1 |
| Haworth, SG; Hislop, AA | 1 |
| De Wolf, D | 1 |
| Dias, B; Fine, N; Mehta, S; Shoemaker, G | 1 |
| Berger, RM; Bouma, BJ; Bresser, P; de Bruin-Bon, RH; Duffels, MG; Hoendermis, ES; Mulder, BJ; Nieuwkerk, PT; van Dijk, AP; van Loon, RL; Vis, JC | 1 |
| Dessy, H; Dewolf, D; Gewillig, M; Mertens, L; Moons, P; Ottenkamp, J; Ovaert, C; Thijs, D | 1 |
| Beghetti, M; Tissot, C | 1 |
| David, S; Feldman, D; Ghanbari, H; Saba, S | 1 |
| Cai, XM; Ji, G; Liu, JF; Su, ZK; Xu, ZM; Zhu, LM | 1 |
| Hirono, K; Ichida, F; Miyawaki, T; Nakamura, T; Taguchi, M; Watanabe, K; Yoshimura, N | 1 |
| Franks, C; Hall, K; Kermeen, FD; McNeil, K; O'Brien, K; Radford, D; Seale, H | 1 |
| Barst, RJ; Brand, M; Ivy, DD; Lemarié, JC; Rosenberg, D; Rosenzweig, EB | 1 |
| Foster, H; Haworth, SG; Hislop, AA; Moledina, S; Schulze-Neick, I | 1 |
| Clarke, B; Hadi, H; Hamid, T; Mahadevan, V | 1 |
| Berger, RM; Bouma, BJ; de Bruin-Bon, RH; Duffels, MG; Hoendermis, ES; Mulder, BJ; Mulder, P; van Dijk, AP; Vis, JC | 1 |
| Bouma, BJ; Budts, W; Celermajer, D; Cordina, R; Gatzoulis, MA; Mulder, BJ; Mullen, MP; Schuuring, MJ; Vis, JC | 1 |
| Argiento, P; Bossone, E; Calabrò, R; Correra, A; D'Alto, M; D'Andrea, A; Papa, S; Romeo, E; Russo, MG; Sarubbi, B; Scognamiglio, G; Vizza, CD | 1 |
| Clarke, B; Griffiths, L; Mahadevan, VS; Monfredi, O | 1 |
| Franklin, WJ; Parekh, DR; Safdar, Z | 1 |
| Chin, T; Do, P; Nussbaum, E; Parsapour, K; Randhawa, I | 1 |
| D'Alto, M; Mahadevan, VS | 1 |
| Baptista, R; Castro, G; da Silva, AM; Monteiro, P; Providência, LA | 1 |
| Bouma, BJ; de Bruin-Bon, RH; Mulder, BJ; Pieper, PG; Schuuring, MJ; Sieswerda, GT; van Dijk, AP; van Melle, JP; Vis, JC; Vliegen, HW | 1 |
| Apostolopoulou, SC; Cokkinos, DV; Manginas, A; Rammos, S | 2 |
| Schulze-Neick, I | 1 |
| Apostolopoulou, SC; Papagiannis, J; Rammos, S | 1 |
| Berger, F; Ewert, P; Gilbert, N; Lange, PE; Luther, YC; Miera, O; Nagdyman, N; Schulze-Neick, I | 1 |
| Benza, RL; Bourge, RC; Coffey, CS; Pamoukian, SV; Pinderski, LJ; Rayburn, BK; Tallaj, JA | 1 |
| Beghetti, M; Gressin, V; Humbert, M; Iserin, L; Petit, J; Simonneau, G; Sitbon, O | 1 |
| Berger, F; Ewert, P; Fehske, W; Gilbert, N; Lange, PE; Lunze, K; Mebus, S; Miera, O; Mühler, EG; Schulze-Neick, I; Uhlemann, F | 1 |
| Diller, GP; Dimopoulos, K; Gatzoulis, MA; Gibbs, JS; Harries, C; Kaya, MG; Koltsida, E; Li, W; Uebing, A | 1 |
| Berger, RM; Duffels, MG; Hillege, HL; Hoendermis, ES; Mulder, BJ; van Loon, RL; Vonk-Noordegraaf, A | 1 |
| Durongpisitkul, K; Jakrapanichakul, D; Sompradikul, S | 1 |
10 review(s) available for bosentan anhydrous and Abnormality, Heart
| Article | Year |
|---|---|
Pharmacology Management in Improving Exercise Capacity of Patients with Fontan Circulation: A Systematic Review and Meta-analysis.
Topics: Bosentan; Exercise Test; Exercise Tolerance; Fontan Procedure; Heart Defects, Congenital; Humans; Quality of Life; Sildenafil Citrate; Sulfonamides; Treatment Outcome | 2022 |
Efficacy and Safety of Long-Term Oral Bosentan in Different Types of Pulmonary Arterial Hypertension: A Systematic Review and Meta-Analysis.
Topics: Antihypertensive Agents; Bosentan; Connective Tissue Diseases; Exercise; Familial Primary Pulmonary Hypertension; Heart Defects, Congenital; Hemodynamics; HIV Infections; Humans; Observational Studies as Topic; Pulmonary Arterial Hypertension | 2021 |
The efficiency of endothelin receptor antagonist bosentan for pulmonary arterial hypertension associated with congenital heart disease: A systematic review and meta-analysis.
Topics: Adolescent; Adult; Bosentan; Child; Child, Preschool; Endothelin Receptor Antagonists; Familial Primary Pulmonary Hypertension; Heart Defects, Congenital; Humans; Infant; Middle Aged; Sulfonamides; Treatment Outcome; Young Adult | 2018 |
Safety and tolerability evaluation of oral bosentan in adult congenital heart disease associated pulmonary arterial hypertension: a systematic review and meta-analysis.
Topics: Administration, Oral; Adult; Antihypertensive Agents; Bosentan; Drug Evaluation; Female; Heart Defects, Congenital; Humans; Hypertension, Pulmonary; Male; Sulfonamides | 2014 |
Pulmonary vasodilator therapy in the failing Fontan circulation: rationale and efficacy.
Topics: Bosentan; Cardiac Output; Endothelin Receptor Antagonists; Fontan Procedure; Heart Defects, Congenital; Heart Failure; Humans; Phenylpropionates; Phosphodiesterase 5 Inhibitors; Postoperative Complications; Pulmonary Circulation; Pyridazines; Sildenafil Citrate; Sulfonamides; Vascular Resistance; Vasodilator Agents | 2015 |
Drug therapy in the prevention of failure of the Fontan circulation: a systematic review.
Topics: Bosentan; Endothelin Receptor Antagonists; Exercise Test; Exercise Tolerance; Fontan Procedure; Heart Defects, Congenital; Hemodynamics; Humans; Iloprost; Randomized Controlled Trials as Topic; Sildenafil Citrate; Sulfonamides; Treatment Outcome; Vasodilator Agents | 2016 |
Pulmonary arterial hypertension in adults with congenital heart disease: distinct differences from other causes of pulmonary arterial hypertension and management implications.
Topics: Adult; Antihypertensive Agents; Blood Pressure; Bosentan; Heart Defects, Congenital; Humans; Hypertension, Pulmonary; Prognosis; Pulmonary Artery; Sulfonamides | 2008 |
Endothelin receptor antagonist therapy in congenital heart disease with shunt-associated pulmonary arterial hypertension: a qualitative systematic review.
Topics: Antihypertensive Agents; Bosentan; Eisenmenger Complex; Endothelin Receptor Antagonists; Exercise Test; Heart Defects, Congenital; Hemodynamics; Humans; Hypertension, Pulmonary; Pulmonary Circulation; Sulfonamides | 2009 |
Successful management of plastic bronchitis in a child post Fontan: case report and literature review.
Topics: Antihypertensive Agents; Bosentan; Bronchitis; Bronchoscopy; Child; Combined Modality Therapy; Drug Therapy, Combination; Expectorants; Female; Fontan Procedure; Heart Defects, Congenital; Humans; Piperazines; Purines; Sildenafil Citrate; Sulfonamides; Sulfones; Tissue Plasminogen Activator; Treatment Outcome; Vasodilator Agents | 2012 |
Pulmonary arterial hypertension associated with congenital heart disease.
Topics: Antihypertensive Agents; Bosentan; Clinical Trials as Topic; Comorbidity; Down Syndrome; Eisenmenger Complex; Endothelium, Vascular; Epoprostenol; Health Behavior; Heart Defects, Congenital; Heart Transplantation; Humans; Hypertension, Pulmonary; Lung Transplantation; Oxygen Inhalation Therapy; Phosphodiesterase 5 Inhibitors; Piperazines; Practice Guidelines as Topic; Pulmonary Circulation; Purines; Sildenafil Citrate; Sulfonamides; Sulfones; Thrombosis | 2012 |
12 trial(s) available for bosentan anhydrous and Abnormality, Heart
| Article | Year |
|---|---|
The efficacy of bosentan combined with vardenafil in the treatment of postoperative pulmonary hypertension in children with congenital heart disease: A protocol of randomized controlled trial.
Topics: Bosentan; Child; Drug Therapy, Combination; Endothelin Receptor Antagonists; Heart Defects, Congenital; Humans; Hypertension, Pulmonary; Phosphodiesterase 5 Inhibitors; Postoperative Complications; Randomized Controlled Trials as Topic; Vardenafil Dihydrochloride | 2021 |
The effect of bosentan on exercise capacity in Fontan patients; rationale and design for the TEMPO study.
Topics: Bosentan; Child; Child, Preschool; Cyclic N-Oxides; Double-Blind Method; Endothelin Receptor Antagonists; Exercise Test; Female; Fontan Procedure; Heart Defects, Congenital; Humans; Male; Sulfonamides; Treatment Outcome | 2013 |
[Efficacy of oral bosentan for treatment of congenital heart disease-associated pulmonary arterial hypertension].
Topics: Administration, Oral; Antihypertensive Agents; Bosentan; Heart Defects, Congenital; Humans; Hypertension, Pulmonary; Sulfonamides | 2014 |
Efficacy of Bosentan in patients after Fontan procedures: a double-blind, randomized controlled trial.
Topics: Adolescent; Bosentan; Child; Double-Blind Method; Female; Follow-Up Studies; Fontan Procedure; Heart Defects, Congenital; Humans; Liver; Male; Palliative Care; Prognosis; Sulfonamides; Treatment Outcome | 2016 |
The effect of bosentan in patients with a failing Fontan circulation.
Topics: Adolescent; Adult; Antihypertensive Agents; Bosentan; Child; Child, Preschool; Female; Follow-Up Studies; Fontan Procedure; Heart Defects, Congenital; Humans; Hypertension, Pulmonary; Male; Pilot Projects; Pulmonary Circulation; Retrospective Studies; Sulfonamides; Treatment Outcome; Young Adult | 2009 |
Bosentan induces clinical and hemodynamic improvement in candidates for right-sided heart bypass surgery.
Topics: Antihypertensive Agents; Blood Pressure; Bosentan; Child, Preschool; Female; Fontan Procedure; Heart Defects, Congenital; Hemodynamics; Humans; Hypertension, Pulmonary; Infant; Male; Pulmonary Artery; Sulfonamides; Treatment Outcome; Vascular Resistance | 2010 |
Therapy for pulmonary arterial hypertension due to congenital heart disease and Down's syndrome.
Topics: Administration, Oral; Adult; Antihypertensive Agents; Bosentan; Down Syndrome; Exercise Tolerance; Familial Primary Pulmonary Hypertension; Female; Follow-Up Studies; Heart Defects, Congenital; Hemodynamics; Humans; Hypertension, Pulmonary; Male; Middle Aged; Prospective Studies; Sulfonamides; Treatment Outcome; Young Adult | 2013 |
Impact of bosentan on exercise capacity in adults after the Fontan procedure: a randomized controlled trial.
Topics: Adolescent; Adult; Antihypertensive Agents; Bosentan; Cardiac Output; Echocardiography; Exercise; Exercise Test; Female; Follow-Up Studies; Fontan Procedure; Heart Defects, Congenital; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Postoperative Period; Prospective Studies; Quality of Life; Severity of Illness Index; Sulfonamides; Treatment Outcome; Young Adult | 2013 |
Effect of the oral endothelin antagonist bosentan on the clinical, exercise, and haemodynamic status of patients with pulmonary arterial hypertension related to congenital heart disease.
Topics: Administration, Oral; Adult; Antihypertensive Agents; Bosentan; Chronic Disease; Exercise; Exercise Tolerance; Female; Heart Defects, Congenital; Hemodynamics; Humans; Hypertension, Pulmonary; Male; Oximetry; Sulfonamides; Treatment Outcome | 2005 |
Initial experience with bosentan (Tracleer) as treatment for pulmonary arterial hypertension (PAH) due to congenital heart disease in infants and young children.
Topics: Antihypertensive Agents; Bosentan; Child; Child, Preschool; Female; Heart Defects, Congenital; Humans; Hypertension, Pulmonary; Infant; Male; Palliative Care; Pilot Projects; Pulmonary Artery; Sulfonamides; Treatment Outcome | 2005 |
Efficacy of bosentan in a small cohort of adult patients with pulmonary arterial hypertension related to congenital heart disease.
Topics: Administration, Oral; Adult; Antihypertensive Agents; Bosentan; Drug Administration Schedule; Female; Follow-Up Studies; Heart Defects, Congenital; Humans; Hypertension, Pulmonary; Male; Middle Aged; Sulfonamides; Treatment Outcome | 2006 |
Long-term oral bosentan treatment in patients with pulmonary arterial hypertension related to congenital heart disease: a 2-year study.
Topics: Administration, Oral; Adolescent; Adult; Antihypertensive Agents; Bosentan; Child; Exercise Tolerance; Female; Follow-Up Studies; Heart Defects, Congenital; Humans; Hypertension, Pulmonary; Male; Prospective Studies; Sulfonamides; Treatment Outcome | 2007 |
31 other study(ies) available for bosentan anhydrous and Abnormality, Heart
| Article | Year |
|---|---|
[Evidence base for specific pulmonary vasodilators in adults with congenital heart disease].
Topics: Adult; Antihypertensive Agents; Bosentan; Eisenmenger Complex; Endothelin Receptor Antagonists; Heart Defects, Congenital; Humans; Hypertension, Pulmonary; Phosphodiesterase 5 Inhibitors; Prostaglandins; Pulmonary Arterial Hypertension; Randomized Controlled Trials as Topic; Vasodilator Agents | 2021 |
From an innocent heart murmur to pulmonary arterial hypertension.
Topics: Antihypertensive Agents; Bosentan; Child, Preschool; Female; Heart Defects, Congenital; Heart Murmurs; Humans; Oximetry; Pulmonary Arterial Hypertension; Truncus Arteriosus, Persistent | 2019 |
Pulmonary Vasodilator Therapy in Children with Single Ventricle Physiology: Effects on Saturation and Pulmonary Arterial Pressure.
Topics: Adolescent; Arterial Pressure; Bosentan; Child; Child, Preschool; Drug Therapy, Combination; Exercise Tolerance; Female; Heart Defects, Congenital; Heart Ventricles; Humans; Hypertension, Pulmonary; Infant; Male; Retrospective Studies; Sildenafil Citrate; Treatment Outcome; United Kingdom; Vascular Resistance; Vasodilator Agents | 2020 |
Definition and Management of Segmental Pulmonary Hypertension.
Topics: Bosentan; Cardiac Surgical Procedures; Disease Management; Endothelin Receptor Antagonists; Heart Defects, Congenital; Humans; Hypertension, Pulmonary; Vascular Malformations | 2018 |
Long-term results of treatment with bosentan in adult Eisenmenger's syndrome patients with Down's syndrome related to congenital heart disease.
Topics: Adolescent; Adult; Antihypertensive Agents; Bosentan; Down Syndrome; Eisenmenger Complex; Exercise Test; Female; Follow-Up Studies; Heart Defects, Congenital; Humans; Male; Retrospective Studies; Sulfonamides; Time Factors; Treatment Outcome; Young Adult | 2013 |
Safety and tolerability of targeted therapies for pulmonary hypertension in children.
Topics: Antihypertensive Agents; Bosentan; Child; Child, Preschool; Drug Therapy, Combination; Female; Heart Defects, Congenital; Humans; Hypertension, Pulmonary; Infant; Longitudinal Studies; Male; Piperazines; Purines; Retrospective Studies; Sildenafil Citrate; Sulfonamides; Sulfones; Treatment Outcome; Vasodilator Agents | 2014 |
Combining bosentan and sildenafil in pulmonary arterial hypertension patients failing monotherapy: real-world insights.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Bosentan; Cause of Death; Child; Connective Tissue Diseases; Drug Therapy, Combination; Exercise Test; Familial Primary Pulmonary Hypertension; Female; Heart Defects, Congenital; Hemodynamics; Humans; Hypertension, Pulmonary; Italy; Kaplan-Meier Estimate; Male; Middle Aged; Retrospective Studies; Sildenafil Citrate; Sulfonamides; Survival Rate; Treatment Outcome; Vasodilator Agents; Young Adult | 2015 |
From bosentan to macitentan for pulmonary arterial hypertension and adult congenital heart disease: Further improvement?
Topics: Adult; Antihypertensive Agents; Bosentan; Cohort Studies; Drug Substitution; Female; Follow-Up Studies; Heart Defects, Congenital; Humans; Hypertension, Pulmonary; Male; Middle Aged; Prospective Studies; Pyrimidines; Sulfonamides | 2017 |
Endothelin receptor antagonists improve exercise tolerance and oxygen saturations in patients with Eisenmenger syndrome and congenital heart defects.
Topics: Administration, Oral; Adult; Antihypertensive Agents; Bosentan; Dose-Response Relationship, Drug; Drug Administration Schedule; Eisenmenger Complex; Endothelin A Receptor Antagonists; Endothelin B Receptor Antagonists; Exercise Test; Female; Heart Defects, Congenital; Humans; Isoxazoles; Male; Middle Aged; Oxygen; Retrospective Studies; Sulfonamides; Thiophenes | 2008 |
Treatment and survival in children with pulmonary arterial hypertension: the UK Pulmonary Hypertension Service for Children 2001-2006.
Topics: Adolescent; Bosentan; Case-Control Studies; Child; Child, Preschool; Epoprostenol; Female; Heart Defects, Congenital; Humans; Hypertension, Pulmonary; Infant; Kaplan-Meier Estimate; Lung Transplantation; Male; Nifedipine; Piperazines; Purines; Retrospective Studies; Sildenafil Citrate; Sulfonamides; Sulfones; Survival Rate; United Kingdom; Vasodilator Agents | 2009 |
Clinical practice: pulmonary hypertension in children.
Topics: Activin Receptors, Type II; Antigens, CD; Antihypertensive Agents; Bone Morphogenetic Protein Receptors, Type II; Bosentan; Calcium Channel Blockers; Child; Electrocardiography; Endoglin; Heart Defects, Congenital; Humans; Hypertension, Pulmonary; Incidence; Piperazines; Point Mutation; Prevalence; Purines; Receptors, Cell Surface; Sildenafil Citrate; Sulfonamides; Sulfones; Vasodilator Agents | 2009 |
Effect of bosentan on exercise capacity and quality of life in adults with pulmonary arterial hypertension associated with congenital heart disease with and without Down's syndrome.
Topics: Adult; Age Factors; Aged; Antihypertensive Agents; Bosentan; Down Syndrome; Exercise Test; Exercise Tolerance; Female; Follow-Up Studies; Heart Defects, Congenital; Humans; Hypertension, Pulmonary; Magnetic Resonance Imaging; Male; Middle Aged; Probability; Quality of Life; Retrospective Studies; Risk Assessment; Severity of Illness Index; Sex Factors; Sulfonamides; Treatment Outcome; Young Adult | 2009 |
Pulmonary arterial hypertension and congenital heart disease: targeted therapies and operability.
Topics: Aged; Antihypertensive Agents; Bosentan; Child; Female; Follow-Up Studies; Heart Defects, Congenital; Hemodynamics; Humans; Hypertension, Pulmonary; Recurrence; Sulfonamides | 2009 |
Unilateral absence of a left pulmonary artery: successful therapeutic response to a combination of bosentan and warfarin.
Topics: Anticoagulants; Antihypertensive Agents; Bosentan; Diagnostic Imaging; Drug Therapy, Combination; Electrocardiography; Female; Heart Defects, Congenital; Humans; Hypertension, Pulmonary; Middle Aged; Pulmonary Artery; Sulfonamides; Warfarin | 2009 |
[Outcome of oral bosentan in children with congenital heart disease associated pulmonary arterial hypertension].
Topics: Adolescent; Antihypertensive Agents; Bosentan; Child; Child, Preschool; Female; Follow-Up Studies; Heart Defects, Congenital; Humans; Hypertension, Pulmonary; Infant; Male; Prospective Studies; Sulfonamides | 2009 |
Endothelin receptor antagonists are an effective long term treatment option in pulmonary arterial hypertension associated with congenital heart disease with or without trisomy 21.
Topics: Adult; Antihypertensive Agents; Bosentan; Confidence Intervals; Down Syndrome; Endothelin Receptor Antagonists; Exercise Test; Exercise Tolerance; Female; Heart Defects, Congenital; Humans; Hypertension; Male; Prospective Studies; Pulmonary Artery; Sulfonamides; Time Factors; Walking | 2010 |
Long-term outcomes in children with pulmonary arterial hypertension treated with bosentan in real-world clinical settings.
Topics: Antihypertensive Agents; Bosentan; Child; Connective Tissue Diseases; Disease Progression; Female; Heart Defects, Congenital; Humans; Hypertension, Pulmonary; Male; Retrospective Studies; Sulfonamides; Treatment Outcome | 2010 |
Long-term efficacy of bosentan in treatment of pulmonary arterial hypertension in children.
Topics: Adolescent; Algorithms; Antihypertensive Agents; Bosentan; Child; Child, Preschool; Disease Progression; Familial Primary Pulmonary Hypertension; Female; Follow-Up Studies; Heart Defects, Congenital; Humans; Hypertension, Pulmonary; Male; Pulmonary Medicine; Retrospective Studies; Sulfonamides; Treatment Outcome | 2011 |
The pressure wire as a diagnostic tool in patients with congenital cardiac disease.
Topics: Adult; Antihypertensive Agents; Bosentan; Cardiac Catheterization; Dyspnea; Female; Heart Defects, Congenital; Heart Valve Prosthesis; Hemodynamics; Humans; Hypertension, Pulmonary; Male; Sulfonamides; Young Adult | 2011 |
Prolonged beneficial effect of bosentan treatment and 4-year survival rates in adult patients with pulmonary arterial hypertension associated with congenital heart disease.
Topics: Adult; Antihypertensive Agents; Bosentan; Down Syndrome; Familial Primary Pulmonary Hypertension; Female; Heart Defects, Congenital; Humans; Hypertension, Pulmonary; Male; Middle Aged; Sulfonamides; Survival Rate; Time Factors | 2013 |
Treatment of segmental pulmonary artery hypertension in adults with congenital heart disease.
Topics: Adult; Antihypertensive Agents; Bosentan; Familial Primary Pulmonary Hypertension; Female; Heart Defects, Congenital; Humans; Hypertension, Pulmonary; Male; Retrospective Studies; Sulfonamides; Young Adult | 2013 |
Efficacy and safety of bosentan for pulmonary arterial hypertension in adults with congenital heart disease.
Topics: Adult; Aged; Alanine Transaminase; Antihypertensive Agents; Aspartate Aminotransferases; Bosentan; Down Syndrome; Exercise Tolerance; Female; Heart Defects, Congenital; Hemoglobins; Humans; Hypertension, Pulmonary; Male; Middle Aged; Oxygen; Retrospective Studies; Sex Factors; Sulfonamides | 2011 |
Adult congenital heart disease and pulmonary arterial hypertension: the Texas Adult Congenital Heart Program experience.
Topics: Adult; Algorithms; Antihypertensive Agents; Bosentan; Endothelin Receptor Antagonists; Epoprostenol; Familial Primary Pulmonary Hypertension; Heart Defects, Congenital; Hospitals, Pediatric; Humans; Hypertension, Pulmonary; Phenylpropionates; Phosphodiesterase 5 Inhibitors; Prevalence; Pyridazines; Sulfonamides; Texas; Transition to Adult Care | 2011 |
Long-term effect of bosentan in pulmonary hypertension associated with complex congenital heart disease.
Topics: Adult; Antihypertensive Agents; Bosentan; Familial Primary Pulmonary Hypertension; Female; Follow-Up Studies; Heart Defects, Congenital; Humans; Hypertension, Pulmonary; Male; Prospective Studies; Sulfonamides; Time Factors | 2013 |
[PAH in congenital heart defects--therapeutic experiences with children and adults].
Topics: Antihypertensive Agents; Bosentan; Child; Clinical Trials as Topic; Endothelin Receptor Antagonists; Heart Defects, Congenital; Heart Septal Defects; Humans; Hypertension, Pulmonary; Sulfonamides; Treatment Outcome; Vascular Resistance | 2005 |
Bosentan induces clinical, exercise and hemodynamic improvement in a pre-transplant patient with plastic bronchitis after Fontan operation.
Topics: Abnormalities, Multiple; Adolescent; Bosentan; Bronchitis; Exercise Tolerance; Follow-Up Studies; Fontan Procedure; Heart Defects, Congenital; Heart Transplantation; Hemodynamics; Humans; Male; Preoperative Care; Prosthesis-Related Infections; Risk Assessment; Sulfonamides; Treatment Outcome; Waiting Lists | 2005 |
Bosentan for the treatment of pulmonary arterial hypertension associated with congenital heart defects.
Topics: Adolescent; Adult; Antihypertensive Agents; Bosentan; Child; Drug Therapy, Combination; Exercise Test; Female; Heart Defects, Congenital; Humans; Hypertension, Pulmonary; Male; Middle Aged; Prostaglandins, Synthetic; Pulmonary Circulation; Retrospective Studies; Sulfonamides; Treatment Outcome; Vascular Resistance; Walking | 2006 |
First experience with an oral combination therapy using bosentan and sildenafil for pulmonary arterial hypertension.
Topics: Administration, Oral; Adolescent; Adult; Antihypertensive Agents; Bosentan; Child; Child, Preschool; Drug Therapy, Combination; Endothelin Receptor Antagonists; Exercise Test; Heart Defects, Congenital; Humans; Hypertension, Pulmonary; Middle Aged; Phosphodiesterase Inhibitors; Piperazines; Prospective Studies; Purines; Sildenafil Citrate; Sulfonamides; Sulfones; Treatment Outcome | 2006 |
Long-term safety, tolerability and efficacy of bosentan in adults with pulmonary arterial hypertension associated with congenital heart disease.
Topics: Adult; Aged; Antihypertensive Agents; Bosentan; Eisenmenger Complex; Exercise Tolerance; Follow-Up Studies; Heart Defects, Congenital; Humans; Hypertension, Pulmonary; Middle Aged; Oxygen; Safety; Sulfonamides | 2007 |
Long-term effect of bosentan in adults versus children with pulmonary arterial hypertension associated with systemic-to-pulmonary shunt: does the beneficial effect persist?
Topics: Adolescent; Adult; Antihypertensive Agents; Bosentan; Child; Child, Preschool; Eisenmenger Complex; Exercise Tolerance; Female; Follow-Up Studies; Heart Defects, Congenital; Humans; Hypertension, Pulmonary; Male; Middle Aged; Pulmonary Wedge Pressure; Sulfonamides; Time Factors; Treatment Outcome; Vascular Resistance | 2007 |
A retrospective study of bosentan in pulmonary arterial hypertension associated with congenital heart disease.
Topics: Adolescent; Adult; Antihypertensive Agents; Bosentan; Databases as Topic; Eisenmenger Complex; Endothelins; Exercise Test; Female; Health Status; Health Status Indicators; Heart Defects, Congenital; Heart Ventricles; Humans; Hypertension, Pulmonary; Male; Middle Aged; Pulmonary Artery; Retrospective Studies; Sulfonamides; Systole; Time Factors; Treatment Outcome | 2008 |